Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Atomoxetine Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 826Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Apnimed Announces Positive Topline Results for MARIPOSA Trial of AD109
    Apnimed Announces Positive Topline Results for MARIPOSA Trial of AD109

    17 Oct 2022

    // PRESS RELEASE

    https://apnimed.com/apnimed-announces-positive-topline-results-for-mariposa-trial-of-ad109/

    PRESS RELEASE
    17 Oct 2022
    Share Share
    Apnimed to Participate in the Annual Needham Biotech Company Virtual 1x1 Forum
    Apnimed to Participate in the Annual Needham Biotech Company Virtual 1x1 Forum

    12 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221012005118/en

    BUSINESSWIRE
    12 Oct 2022
    Share Share
    New Data Show Meaningful Improvements for AD504 in Obstructive Sleep Apnea
    New Data Show Meaningful Improvements for AD504 in Obstructive Sleep Apnea

    02 Jun 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220602005151/en

    BUSINESSWIRE
    02 Jun 2022
    Share Share
    OWP Pharma Announces IND Authorization for the 1st-Ever Oral Liquid Formulation
    OWP Pharma Announces IND Authorization for the 1st-Ever Oral Liquid Formulation

    17 Nov 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/11/17/2336301/0/en/OWP-Pharmaceuticals-Announces-IND-Authorization-for-the-First-Ever-Oral-Liquid-Formulation-of-Atomoxetine-Hydrochloride-for-the-Treatment-of-Attention-Deficit-Hyperactivity-Disorde.html

    GLOBENEWSWIRE
    17 Nov 2021
    Share Share
    Apnimed sees positives in new sleep apnea drug data
    Apnimed sees positives in new sleep apnea drug data

    14 Oct 2021

    // Ben Adams FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/apnimed-sees-positives-midstage-data-for-its-attempt-at-drugging-sleep-apnea-problem

    Ben Adams FIERCEBIOTECH
    14 Oct 2021
    Share Share
    OWP Pharmaceuticals Announces Patent Application for the First-Ever Oral Liquid
    OWP Pharmaceuticals Announces Patent Application for the First-Ever Oral Liquid

    22 Apr 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/04/22/2215011/0/en/OWP-Pharmaceuticals-Announces-Patent-Application-for-the-First-Ever-Oral-Liquid-Formulation-of-Atomoxetine-Hydrochloride-for-the-Treatment-of-Attention-Deficit-Hyperactivity-Disord.html

    GLOBENEWSWIRE
    22 Apr 2021
    Share Share